{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:13:25Z","timestamp":1761902005234,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.msard.2022.103893","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T21:07:37Z","timestamp":1652735257000},"page":"103893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4212-906X","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Moura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Sam\u00f5es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Boleixa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernestina","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Martins","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.msard.2022.103893_bib0001","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13598","article-title":"Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis","volume":"51","author":"Aimo","year":"2021","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.msard.2022.103893_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102886","article-title":"COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America","volume":"51","author":"Alonso","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103893_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102174","article-title":"The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic","volume":"43","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2022.103893_bib0004","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-021-02424-0","article-title":"Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale \u2013 a bicentric retrospective study","volume":"21","author":"Barz","year":"2021","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.103893_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001001","article-title":"COVID-19 among patients with multiple sclerosis a systematic review","volume":"8","author":"Barzegar","year":"2021","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."},{"key":"10.1016\/j.msard.2022.103893_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.588929","article-title":"Neuromuscular Diseases Care in the Era of COVID-19","volume":"11","author":"Bertran Recasens","year":"2020","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.103893_bib0007","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/imj.12749","article-title":"Consensus guidelines for the investigation and management of encephalitis in adults and children in Australia and New Zealand","volume":"45","author":"Britton","year":"2015","journal-title":"Intern. Med. J."},{"issue":"3","key":"10.1016\/j.msard.2022.103893_bib0008","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.autrev.2018.01.001","article-title":"Diagnosis and management of neuromyelitis optica spectrum disorders - An update","volume":"17","author":"Bruscolini","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2022.103893_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.01053","article-title":"Myasthenia Gravis and COVID-19: clinical characteristics and outcomes","volume":"11","author":"Camelo-Filho","year":"2020","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.103893_bib0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/jns.12435","article-title":"Acute and chronic inflammatory neuropathies and COVID-19 vaccines: Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP)","volume":"26","author":"Doneddu","year":"2021","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"4","key":"10.1016\/j.msard.2022.103893_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22041804","article-title":"The impact of sars-cov-2 infection on the development of neurodegeneration in multiple sclerosis","volume":"22","author":"Dziedzic","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2022.103893_bib0012","first-page":"155","article-title":"Acute encephalitis - diagnosis and management","volume":"18","author":"Ellul","year":"2018","journal-title":"Clin. Med. J. R. Coll. Physic. Lond."},{"issue":"2","key":"10.1016\/j.msard.2022.103893_bib0013","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/ijms23020672","article-title":"Bana\u015b-Z\u0105bczyk A. Disorders of the cholinergic system in COVID-19 era\u2014a review of the latest research","volume":"23","author":"Kopa\u0144ska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.msard.2022.103893_bib0014","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41582-020-0385-8","article-title":"Neurological immunotherapy in the era of COVID-19 \u2014 looking for consensus in the literature","volume":"16","author":"Korsukewitz","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2022.103893_bib0015","article-title":"COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments","author":"Laroni","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"9","key":"10.1016\/j.msard.2022.103893_bib0016","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.103893_bib0017","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2022.103893_bib0018","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00415-020-10015-1","article-title":"COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis","volume":"268","author":"Mantero","year":"2021","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.103893_bib0019","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/jmv.26796","article-title":"Multiple sclerosis and COVID-19: How could therapeutic scenarios change during the pandemic?","volume":"93","author":"Mantero","year":"2021","journal-title":"J. Med. Virol."},{"issue":"12","key":"10.1016\/j.msard.2022.103893_bib0020","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","article-title":"COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)","volume":"19","author":"Muppidi","year":"2020","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2022.103893_bib0021","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41575-021-00480-y","article-title":"COVID-19: Biologic and immunosuppressive therapy in gastroenterology and hepatology","volume":"18","author":"Neurath","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.msard.2022.103893_bib0022","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000835","article-title":"COVID-19 outcomes in MS: observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center","volume":"7","author":"Parrotta","year":"2020","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."},{"issue":"4","key":"10.1016\/j.msard.2022.103893_bib0023","article-title":"Surveillance of the second wave of covid-19 in Europe: longitudinal trend analyses","volume":"7","author":"Post","year":"2021","journal-title":"JMIR Public Heal. Surveill."},{"issue":"3","key":"10.1016\/j.msard.2022.103893_bib0024","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s00415-021-10803-3","article-title":"Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies","volume":"269","author":"Prosperini","year":"2022","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.103893_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42466-021-00143-y","article-title":"Multiple sclerosis is not associated with an increased risk for severe COVID-19: a nationwide retrospective cross-sectional study from Germany","volume":"3","author":"Richter","year":"2021","journal-title":"Neurol. Res. Pract."},{"key":"10.1016\/j.msard.2022.103893_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a north american registry of patients with multiple sclerosis","author":"Salter","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2022.103893_bib0027","article-title":"INSA","author":"Sa\u00fade","year":"2021","journal-title":"Relat\u00f3rio de Situa\u00e7\u00e3o"},{"issue":"3","key":"10.1016\/j.msard.2022.103893_bib0028","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","article-title":"Karnofsky performance status revisited: Reliability, validity, and guidelines","volume":"2","author":"Schag","year":"1984","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.msard.2022.103893_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.595739","article-title":"The role of type I interferons in the pathogenesis and treatment of COVID-19","volume":"11","author":"Schreiber","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2022.103893_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102968","article-title":"The outcome of a national MS-Covid-19 study: what the Turkish MS cohort reveals?","volume":"52","author":"Sen","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103893_bib0031","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012753","article-title":"Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis","author":"Simpson-Yap","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.103893_bib0032","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.103893_bib0033","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force\u2014Second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2022.103893_bib0034","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.7150\/ijbs.58695","article-title":"Glucocorticoids are double-edged sword in the treatment of covid-19 and cancers","volume":"17","author":"Yang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"10","key":"10.1016\/j.msard.2022.103893_bib0035","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1111\/ene.14690","article-title":"COVID-19 in multiple sclerosis patients: Susceptibility, severity risk factors and serological response","volume":"28","author":"Zabalza","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.103893_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103324","article-title":"The MuSC-19 study: the Egyptian Cohort","author":"Zakaria","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2022.103893_bib0037","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00415-020-10112-1","article-title":"COVID-19 infection in NMO\/SD patients: a French survey","volume":"268","author":"Zeidan","year":"2021","journal-title":"J. Neurol."},{"issue":"10229","key":"10.1016\/j.msard.2022.103893_bib0038","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822004047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822004047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:00Z","timestamp":1761901500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822004047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":38,"alternative-id":["S2211034822004047"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103893","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103893"}}